2026. Real-World Safety and Effectiveness of Up to 12 Months of Tralokinumab Treatment in Adults With Atopic Dermatitis Who Discontinued Dupilumab Due to Conjunctivitis. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s729. DOI:https://doi.org/10.25251/1jtrf706.